Literature DB >> 21247534

Gender differences between the Minnesota code and Novacode electrocardiographic prognostication of coronary heart disease in the cardiovascular health study.

Zhu-ming Zhang1, Ronald J Prineas, Doug Case, Bruce M Psaty, Takeki Suzuki, Gregory L Burke.   

Abstract

The Minnesota Code (MC) and Novacode (Nova) are the most widely used electrocardiographic (ECG) classification systems. The comparative strengths of their classifications for Q- and ST-T-wave abnormalities in predicting coronary heart disease (CHD) events and total mortality have not been evaluated separately by gender. We studied standard 12-lead electrocardiograms at rest from 4,988 participants in the Cardiovascular Health Study. Average age at baseline was 73 years, 60% of participants were women 85% were white, and 22% had a history of cardiovascular disease or presence of ECG myocardial infarction by MC or Nova. Starting in 1989 with an average 17-year follow-up, 65% of participants died and 33% had incident CHD in a cohort free of cardiovascular disease at baseline. Of these, electrocardiograms with major Q-wave or major ST-T abnormalities by MC or Nova predicted increased risk for CHD events and total mortality with no significant differences in predictability between men and women. The study also found that women had fewer major Q-wave changes but more major ST-T abnormalities than men. However, there were no gender differences in predicting CHD events and total mortality. In conclusion, ECG classification systems for myocardial infarction/ischemia abnormalities by MC or Nova are valuable and useful for men and women in clinical trials and epidemiologic studies.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21247534      PMCID: PMC3673724          DOI: 10.1016/j.amjcard.2010.11.004

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

1.  Long-term prognostic significance of isolated minor electrocardiographic T-wave abnormalities in middle-aged men free of clinical cardiovascular disease (The Multiple Risk Factor Intervention Trial [MRFIT]).

Authors:  Ronald J Prineas; Greg Grandits; Pentti M Rautaharju; Jerome D Cohen; Zhu Ming Zhang; Richard S Crow
Journal:  Am J Cardiol       Date:  2002-12-15       Impact factor: 2.778

2.  Methodology of ECG interpretation in the Dalhousie program; NOVACODE ECG classification procedures for clinical trials and population health surveys.

Authors:  P M Rautaharju; P J MacInnis; J W Warren; H K Wolf; P M Rykers; H P Calhoun
Journal:  Methods Inf Med       Date:  1990-09       Impact factor: 2.176

3.  The Cardiovascular Health Study: design and rationale.

Authors:  L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman
Journal:  Ann Epidemiol       Date:  1991-02       Impact factor: 3.797

4.  Major electrocardiographic abnormalities in persons aged 65 years and older (the Cardiovascular Health Study). Cardiovascular Health Study Collaborative Research Group.

Authors:  C D Furberg; T A Manolio; B M Psaty; D E Bild; N O Borhani; A Newman; B Tabatznik; P M Rautaharju
Journal:  Am J Cardiol       Date:  1992-05-15       Impact factor: 2.778

5.  Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study.

Authors:  D G Ives; A L Fitzpatrick; D E Bild; B M Psaty; L H Kuller; P M Crowley; R G Cruise; S Theroux
Journal:  Ann Epidemiol       Date:  1995-07       Impact factor: 3.797

6.  Evaluation and comparison of the Minnesota Code and Novacode for electrocardiographic Q-ST wave abnormalities for the independent prediction of incident coronary heart disease and total mortality (from the Women's Health Initiative).

Authors:  Zhu-ming Zhang; Ronald J Prineas; Charles B Eaton
Journal:  Am J Cardiol       Date:  2010-05-13       Impact factor: 2.778

7.  Electrocardiographic abnormalities that predict coronary heart disease events and mortality in postmenopausal women: the Women's Health Initiative.

Authors:  Pentti M Rautaharju; Charles Kooperberg; Joseph C Larson; Andrea LaCroix
Journal:  Circulation       Date:  2006-01-31       Impact factor: 29.690

8.  Comparison of mortality risk for electrocardiographic abnormalities in men and women with and without coronary heart disease (from the Cardiovascular Health Study).

Authors:  Pentti M Rautaharju; Sijian Ge; Jennifer C Nelson; Emily K Marino Larsen; Bruce M Psaty; Curt D Furberg; Zhu-Ming Zhang; John Robbins; John S Gottdiener; Paulo H M Chaves
Journal:  Am J Cardiol       Date:  2005-12-01       Impact factor: 2.778

9.  Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study.

Authors:  B M Psaty; L H Kuller; D Bild; G L Burke; S J Kittner; M Mittelmark; T R Price; P M Rautaharju; J Robbins
Journal:  Ann Epidemiol       Date:  1995-07       Impact factor: 3.797

10.  Major and minor ECG abnormalities in asymptomatic women and risk of cardiovascular events and mortality.

Authors:  Pablo Denes; Joseph C Larson; Donald M Lloyd-Jones; Ronald J Prineas; Philip Greenland
Journal:  JAMA       Date:  2007-03-07       Impact factor: 56.272

View more
  3 in total

1.  Prognostic significance of serial Q/ST-T changes by the Minnesota Code and Novacode in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Zhu-ming Zhang; Ronald J Prineas; Elsayed Z Soliman; Chris Baggett; Gerardo Heiss
Journal:  Eur J Prev Cardiol       Date:  2011-10-13       Impact factor: 7.804

2.  Sex Differences in Biological Markers of Health in the Study of Stress, Aging and Health in Russia.

Authors:  Anna Oksuzyan; Maria Shkolnikova; James W Vaupel; Kaare Christensen; Vladimir M Shkolnikov
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

3.  Trends in electrocardiographic abnormalities and risk of cardiovascular mortality in Lithuania, 1986-2015.

Authors:  Abdonas Tamosiunas; Janina Petkeviciene; Ricardas Radisauskas; Gailute Bernotiene; Dalia Luksiene; Mindaugas Kavaliauskas; Irena Milvidaitė; Dalia Virviciute
Journal:  BMC Cardiovasc Disord       Date:  2019-01-30       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.